Scientists from Jiangsu Hengrui Pharmaceuticals Co. Ltd., Shanghai Senhui Pharmaceutical Co. Ltd. and Shanghai Shengdi Pharmaceutical Co. Ltd. have disclosed antibody-drug conjugates comprising antibodies covalently linked camptothecin derivatives through a linker reported to be useful for the treatment of cancer.

Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for use as an anesthetic.

Shanghai Fosun Pharmaceutical Industry Development Co. Ltd. has patented Myt1 kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.

Mabwell (Shanghai) Bioscience Co. Ltd. has synthesized antibody-drug conjugates comprising antibody or antigen-binding fragment targeting disintegrin and metalloproteinase domain-containing protein 9 (ADAM9) covalently linked to a cytotoxic drug. They are described as potentially useful for the diagnosis and/or treatment of cancer.

Avacta Life Sciences Ltd. has disclosed drug conjugates consisting of a fibroblast activation protein-α (FAPα) cleavable moiety bonded to camptothecin derivatives through a linker that are potentially useful for the treatment of cancer, inflammation and fibrosis.

Hetero Labs Ltd. has reported tyrosine kinase inhibitors that are potentially useful for the treatment of cancer.

Researchers from Ruijin Hospital and Shanghai Jiao Tong University have patented molecular glue degraders, specifically eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) degradation inducers that are potentially useful for the treatment of cancer, autoimmune disease and inflammatory disorders.

Jiangsu Vcare Pharmatech Co. Ltd. has described interleukin-17A (IL-17A) inhibitors reported to be useful for the treatment of psoriasis, psoriatic arthritis and spondyloarthritis.

Singularity Pharma Ltd. has divulged mitragynine analogues that are potentially useful for the treatment of postoperative pain, depression, opioid dependence, opioid withdrawal, inflammatory and psychiatric disorders.

Hinova Pharmaceuticals Inc. has synthesized prodrugs of orforglipron (a glucagon-like peptide 1 receptor [GLP-1R] agonist) for the potential treatment of diabetes, obesity, hypertension, arteriosclerosis, cerebral infarction, arthritis, polycystic ovary syndrome and Parkinson’s disease, among others.